Seres Therapeutics Inc
NASDAQ:MCRB 3:59:52 PM EDT
| Market Cap (Intraday) | 571.43M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $6.30 |
| 50-Day MA | $6.48 |
| 200-Day MA | $16.49 |
Seres Therapeutics Inc Stock, NASDAQ:MCRB
200 Sidney Street, 4th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.945.9626
Number of Employees: 155
Description
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.